Vuélvete ilimitado con Magzter GOLD

Obtenga acceso ilimitado a más de 9000 revistas, periódicos e historias Premium por solo

$149.99

$74.99/Año

Intentar ORO - Gratis

Vuélvete ilimitado con Magzter GOLD

Obtenga acceso ilimitado a más de 9000 revistas, periódicos e historias Premium por solo

$NaN

$NaN/Año

¡Date prisa, oferta por tiempo limitado!

Horas

minutos

artículos de segunda clase

BioSpectrum Asia - BioSpectrum Asia July 2025

Vuélvete ilimitado con Magzter GOLD

Leer BioSpectrum Asia junto con más de 9000 revistas y periódicos con una sola suscripción

Ver catálogo

1 mes

$14.99

1 año $149.99

$74.99

$6/month

Save 50%
Hurry, Offer Ends in 1 Days

Hurry! Offer ends in

21 Hours

22 Mins

55 Secs

(OR)

Suscríbete sólo a BioSpectrum Asia

Regalo BioSpectrum Asia

Cancelar en cualquier momento.

(Sin compromisos) ⓘ

Si no estás satisfecho con tu suscripción, puedes enviarnos un correo electrónico a help@magzter.com dentro de los 7 días posteriores a la fecha de inicio de la suscripción para recibir un reembolso completo. ¡Sin preguntas, lo prometemos! (Nota: No se aplica a compras de números individuales)

Suscripción digital

Acceso instantáneo ⓘ

Suscríbete ahora para comenzar a leer instantáneamente en el sitio web de Magzter, iOS, Android y las aplicaciones de Amazon.

Verificado seguro

pago ⓘ

Magzter es un comerciante verificado de Authorize.Net. Más información

En este número

Medical Advances Soar With APAC’S CLINICAL TRIAL GROWTH It’s a truth universally acknowledged that Asia-Pacific is a hotbed for clinical trials, with multiple reports confirming that it is the only region in the world to have seen a consistent surge in clinical trial activity. The Asia Pacific clinical trials market generated a revenue of $15.91 billion in 2023 and is expected to reach a projected revenue of $25.99 billion by 2030 at a compound annual growth rate of 7.3 per cent, according to the Grand View Research report. Between 2020 and 2025, China, India, Australia, Japan, South Korea, and Singapore emerged as key pillars of Asia-Pacific’s growing clinical trial ecosystem. Together, these six countries accounted for nearly 40,000 trials (39,843 in total). We take a close look at each country’s clinical trial landscape, examining who is leading in which phases, how domestic players compare to multinational sponsors, and which therapeutic areas are seeing the most activity. We also explore the challenges of running trials across such a diverse region.

IRREPLACEABLE HUMAN TOUCH

The trend of virtual and remote healthcare—including diagnostics and treatment—is gaining traction globally. Telemedicine, in particular, saw a rapid acceleration during COVID-19, when in-person consultations were often avoided due to the risk of virus transmission. Both healthcare providers and patients embraced remote care as a safer alternative. According to a GlobalData survey, 56 per cent of healthcare professionals believe that the growth of telemedicine and remote care has enhanced patients’ control over their health management. Among them, 13 per cent strongly agreed, while 26 per cent remained neutral. Only 2 per cent disagreed and 3 per cent strongly disagreed, showing widespread acceptance of this shift.

2 mins

Singapore launches national Familial Hypercholesterolaemia genetic testing programme

The Ministry of Health (MOH), Singapore government, has launched the national Familial Hypercholesterolaemia (FH) genetic testing programme on June 30, 2025, as part of its broader strategy to enhance preventive care in Singapore.

1 mins

New Zealand grants approval to prescribe psilocybin for treatmentresistant depression

Medsafe, New Zealand's regulator of medicines and medical devices, has given approval for psychiatrists to prescribe medicinal psilocybin for treating treatment-resistant depression.

1 mins

AusBiotech & Austrade ink partnership to accelerate.global expansion of life sciences industry

Aus Biotech, Australia's peak body for the life sciences sector, and the Australian Government's Trade and Investment Commission (Austrade) are partnering to accelerate the global growth and expansion of Australian life science companies.

1 mins

Korea Smart Healthcare Association to build next-gen medical platform

The Korea Smart Healthcare Association and SL Foundation have signed a Memorandum of Understanding (MoU) to form a strategic partnership aimed at advancing Korea's medical technology innovation and enhancing global public health.

1 mins

Indonesia and Thailand ink health MoU focusing on global capacity and collaboration

In a series of official visits by the President of the Republic of Indonesia Prabowo Subianto to Thailand, bilateral cooperation between the two countries was strengthened through the signing of a Memorandum of Understanding (MOU) in the health sector.

1 mins

India opens computing facility to boost genomic research

The Indian Council of Medical Research (ICMR), under the Health Ministry, has marked a significant milestone in advancing India's public health research capabilities with the inauguration of its first High Performance Computing (HPC) facility at the ICMR-National Institute of Virology (NIV), Pune.

1 mins

AstraZeneca inks collaboration worth $3.6 B with CSPC Pharma in China

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group.

1 mins

AriBio licenses Alzheimer's drug to Arcera in $600 M deal

AriBio Co., a South Korean biopharmaceutical company specialising in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi, have announced the signing of exclusive licensing and commercialisation, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease.

1 mins

PolyActiva secures AUD $40 M in Series C to advance ocular drug delivery

Australia-based PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, has secured AUD $40 million in Series C funding.

1 mins

Vietnam Vaccine JSC injects $77 M in new manufacturing unit

Vietnam Vaccine Joint Stock Company (VNVC) has begun construction on its 26,000 square meter factory building with an investment of VND2 trillion ($77.17 million).

1 mins

Quadria Group takes control of HealthQuad for launching Fund III with corpus of $300 M

Quadria Group, Asia's leading healthcare-focused private equity platform, has announced the launch of HealthQuad Fund III, with a proposed raise of up to $300 million (target corpus of $200 million with a $100 million greenshoe option).

1 mins

Singapore leads S$10 M national effort to tackle muscle-loss due to ageing

To tackle the growing threat of muscle loss in Singapore's ageing population, SingHealth Duke-NUS Academic Medical Centre will spearhead a S$10 million research initiative into sarcopenia, marking the country's first comprehensive, large-scale programme focused on this condition marked by loss of muscle mass and strength.

1 mins

Serum Institute of India partners with DNDi to advance development of new dengue treatment

Serum Institute of India (SII), a part of Cyrus Poonawalla Group, and the not-for-profit medical research organisation Drugs for Neglected Diseases initiative (DNDi) have signed a Memorandum of Understanding (MoU) to accelerate the clinical development of a monoclonal antibody treatment for dengue that will be affordable and accessible in low- and middle-income countries (LMICs).

1 mins

Sanofi to accelerate development of new global vaccines in Abu Dhabi

The Department of Health - Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, has signed a Memorandum of Understanding (MOU) with Sanofi, a research and development-driven, AI-powered healthcare biopharma company.

1 mins

Lupin, Sino Universal ink license and supply agreement for Tiotropium DPI in China

Indian pharma major Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP), for the commercialisation of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in the Chinese market, for the treatment of chronic obstructive pulmonary disease (COPD).

1 mins

ClavystBio and A*STAR partner to grow medtech ventures in Singapore

ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MOU) to create and grow medtech ventures in Singapore.

1 mins

Olympus announces full market release of AI-powered emphysema screening programme

Japan headquartered medtech firm Olympus Corp. has announced the full market release of its artificial intelligence (AI)-driven emphysema screening programme, SeleCT Screening.

1 mins

Samsung Biologics launches drug screening services, Samsung Organoids

South Korea-based Samsung Biologics, a leading contract development and manufacturing organisation (CDMO), has announced the launch of Samsung Organoids, advanced drug screening services to support clients in drug discovery and development.

1 mins

Brain Navi achieves US FDA approval for neurosurgical robot NaoTrac

Brain Navi Biotechnology, a medical robotics company founded in 2015 in Taiwan by surgeon and serial entrepreneur Jerry Chen, has reached another major milestone.

1 mins

Gene Solutions, Shenzhen USK Bioscience to establish next-gen sequencing lab in Southern China

Vietnam-based startup Gene Solutions and Shenzhen USK Bioscience Co. (USKBio), a molecular diagnostics startup in China, have entered a strategic partnership through a Memorandum of Understanding (MoU).

1 mins

GenepoweRx and MGI Tech to accelerate AI-driven genomic solutions in personalised medicine

Indian startup GenepoweRx, a trailblazer in artificial intelligence (AI)-powered personalised medicine based on genomic insights, has announced a strategic collaboration with China-based MGI Tech Co.

1 mins

HekaBio teams up with Alfresa Holdings accelerating access to innovative therapies in Japan

HekaBio K.K. has announced the signing of a strategic partnership agreement with Alfresa Holdings Corporation, a leading pharmaceutical wholesaler group in Japan.

1 mins

UltraGreen.ai acquires Perfusion Tech

UltraGreen.ai, a Singapore-headquartered leader in surgical imaging technology, has announced the acquisition of Perfusion Tech, a clinical software innovator focused on real-time perfusion quantification during surgical procedures.

1 mins

HekaBio teams up with Alfresa Holdings accelerating access to innovative therapies in Japan

HekaBio K.K. has announced the signing of a strategic partnership agreement with Alfresa Holdings Corporation, a leading pharmaceutical wholesaler group in Japan. As part of this agreement, Alfresa Holdings has also made a capital investment in HekaBio.

1 mins

MarkHerz signs MoU with German university hospital for research on next-generation gene therapies

MarkHerz Inc., a South Korea-based biotechnology startup specialising in AAV-based gene therapies targeting cardiovascular and metabolic diseases, has signed a Memorandum of Understanding (MoU) with Klinikum rechts der Isar, the university hospital affiliated with the Technical University of Munich (TUM), Germany.

1 mins

Joint action plans to tackle viral hepatitis in Africa

Considering the general decline in funding for research and development, Africa Centres for Disease Control and Prevention (Africa CDC), in collaboration with the World Hepatitis Alliance (WHA) and the African Viral Hepatitis Action Group (AVHAG), has developed a capacity-building programme for hepatitis elimination and advocacy.

1 mins

CEPI signs new agreement with US Dept of Defense focusing on disease outbreaks

Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) and the US Department of Defense, Joint Programme Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), have signed a new agreement that will enable the two organisations to collaborate on projects that expand global defences against disease outbreaks.

1 mins

Eastern Caribbean launches project to strengthen pandemic preparedness

A landmark initiative to boost pandemic preparedness and response in the Eastern Caribbean has been launched in Castries, Saint Lucia, bringing renewed focus to building resilient, integrated health systems that can better detect and respond to future health threats.

1 mins

US FDA halts new clinical trials that export Americans' cells for genetic experiments

The US Food and Drug Administration (FDA) has announced an immediate review of new clinical trials that involve sending American citizens' living cells to China and other hostile countries for genetic engineering and subsequent infusion back into US patients, sometimes without their knowledge or consent.

1 mins

Global leaders unite to accelerate cervical cancer elimination efforts

Governments, donors, multilateral institutions, the private sector and partners have announced significant policy, programmatic and financial commitments to eliminate one of the most preventable cancers.

1 mins

UK to boost clinical trials under 10 Year Health Plan

Patients will receive the most cutting-edge treatments years earlier than planned under the government's 10 Year Health Plan, which will speed up clinical trials so the UK becomes a hotbed of innovation.

1 mins

WHO outlines recommendations to protect infants against RSV

The World Health Organization (WHO) has published its first-ever position paper on immunisation products to protect infants against respiratory syncytial virus (RSV) - the leading cause of acute lower respiratory infections in children globally.

1 mins

WHO issues first global guideline to improve pregnancy care for women with sickle cell disease

The World Health Organization (WHO) has released its firstever global guideline on the management of sickle cell disease (SCD) during pregnancy, addressing a critical and growing health challenge that can have life-threatening consequences for both women and babies. Health risks associated with SCD intensify during pregnancy, due to heightened demands on the body's oxygen and nutrient supply.

1 mins

WHO calls for global expansion of midwifery models of care

The World Health Organization (WHO) has released new guidance to help countries adopt and expand midwifery models of care - where midwives serve as the main care provider for women and babies throughout pregnancy, childbirth, and the postnatal period.

1 mins

Medical Advances Soar With APAC’S CLINICAL TRIAL GROWTH

It's universally acknowledged that Asia-Pacific (APAC) is a hotbed for clinical trials, with multiple reports confirming that it is the only region in the world to have seen a consistent surge in clinical trial activity.

10+ mins

Taiwan's biotech gathers momentum

Leader: Backed by coordinated efforts from both government and industry, Taiwan's biotechnology sector is expanding steadily, with revenues reaching approximately $23.3 billion in 2023. The industry is positioning itself as an important player in the global biotech value chain. But what will it take for Taiwan to grow into a $32 billion biotech economy? Let's find out.

7 mins

Japan's strategic medtech alignment with India

Given Japan's ageing population and the increasing number of patients with chronic and lifestyle diseases, Japan's market for medical devices continues to be among the world's largest.

6 mins

“Many US-based firms are actively seeking new opportunities in Asia for R&D partnerships, clinical trials, and commercialisation”

As Hong Kong accelerates its transformation into a global biotech and MedTech powerhouse, BioSpectrum Asia spoke with Andy Wong, Head of Innovation & Technology at Invest Hong Kong (InvestHK), at BIO International in Boston. Wong discussed increasing American interest in Hong Kong's innovation landscape, spotlighted promising local companies, and shared insights on how strategic partnerships, robust policy frameworks, and cross-border collaborations with Mainland China are positioning Hong Kong as a vital bridge between Western innovators and Asia’s thriving biotech ecosystem. Edited excerpts;

4 mins

“APAC is dynamic and rapidly evolving, with tremendous growth in R&D and attractive market conditions”

With cell and gene therapy (CGT) representing a major advancement in medical treatments by directly targeting the root causes of diseases at the cellular or genetic level, GlobalData’s latest report predicts the CGT market to be worth $76 billion by 2030.

5 mins

“The burden on medical and long- term care systems due to ageing is expected to intensify in Japan”

Japan-headquartered Asahi Kasei has appointed Ken Shinomiya, President of Asahi Kasei Life Science, as the Leader of its Healthcare Sector in April this year. Under Shinomiya, Asahi Kasei’s Healthcare Sector plans to further advance its portfolio and global presence of pharmaceuticals, life science, and critical care products and services. BioSpectrum Asia took this opportunity to interact with the new leader to find out more about the company’s growth plans within Japan and internationally. Edited excerpts:

4 mins

"By removing structural dependence, we unlock the full potential of AI for drug discovery"

Gero, a Singapore-based biotech company focused on aging and chronic diseases, launched ProtoBind-Diff, an AI model that generates small molecules for specific protein targets—using only the amino acid sequence, without needing 3D structural data.

5 mins

Why AI-Enabled ‘Dirty Drugs’ are Future for Longevity Medicine

Ageing is not a result of a single malfunction; it’s a gradual, systemic breakdown that touches everything. Researchers have long understood this and have mapped the tangled web of genes, pathways, enzymes, and signalling molecules involved. For decades, the pharmaceutical industry tried to simplify its way through the complexity of ageing. But now, with AI and polypharmacology, we finally have the tools to meet that complexity on its terms.

5 mins

PCI Growth in Malaysia: Innovations Transforming Cardiovascular Care

The number of PCI procedures with stents has risen dramatically in Malaysia in recent years and is set to see further significant growth, driven by rising CVD prevalence, demographic shifts, and technological advancements. Since the introduction of DES, there has not been a successful major technological advance in stent technology for over two decades. However, results from the INFINITY-SWEDEHEART Trial, published in The Lancet in November 2024 indicate that a novel technology is set to challenge the dominance of DES in the PCI market.

4 mins

Medison expands global leadership team

Israel-based Medison, the creator of a first-of-its-kind unified global commercialisation platform that accelerates the launch of breakthrough therapies in markets beyond the US, Western Europe, and Japan, has announced two key additions to its global leadership team: c. Shay Tamari, newly appointed Chief Business Officer, will lead Medison's global corporate development strategy.

1 mins

Royal Society elects Duke-NUS' Prof. Wong Tien Yin for Fellowship

Recognised for his invaluable contributions to science and innovation, Professor Wong Tien Yin from Singapore-based Duke-NUS' Office of Academic Medicine has been elected to the Fellowship of the Royal Society, the UK's national academy of sciences.

1 mins

Sun Pharma names Kirti Ganorkar as new Managing Director

Sun Pharmaceutical Industries, based in India, has announced the appointment of Kirti Ganorkar as the Managing Director (MD) to succeed Dilip Shanghvi, effective September 1, 2025, with the entire business and all functions reporting to him.

1 mins

Sun Pharma names Kirti Ganorkar as new Managing Director

1 mins

Singapore designs new biomaterial to show how ageing in heart could be reversed

A new lab-grown material has revealed that some of the effects of ageing in the heart may be slowed and even reversed.

1 mins

Australia develops AI tool to ensure colorectal cancer patients receive correct dose of chemotherapy

University of Melbourne and Western Health researchers in Australia have developed a new artificial intelligence (AI) tool to prevent cancer patients from receiving incorrect doses of chemotherapy.

1 mins

India discovers novel nanozyme to prevent excess blood clotting

Researchers at the Indian Institute of Science (IISc), Bengaluru have developed an artificial metal-based nanozyme that can potentially be used to clamp down on abnormal blood clotting caused by conditions like pulmonary thromboembolism (PTE).

1 mins

Korea focuses on exercise-induced protein to revive ageing muscles and bones

A joint research team, at the Korea Research Institute of Bioscience and Biotechnology and Chonnam National University, South Korea, has discovered a key protein, CLCF1 (cardiotrophinlike cytokine factor 1), that plays a central role in mediating the health benefits of physical activity.

1 mins

Japan transforms engineered heart tissues for precise drug testing

A research team at Kyoto University in Japan has developed a novel engineered heart tissue (EHT) platform using low-absorption polystyrene (PS) that overcomes the limitations of current devices, enabling rigorous in vitro evaluation of drug responses and streamlining preclinical testing by minimising the need for conventional animal experiments.

1 mins

Hong Kong leads global drug development using new dual immunotherapy

A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a 'dual immunotherapy' combinationnivolumab and ipilimumab (NIVO+IPI), in the treatment of liver cancer patients.

1 mins

IonOpticks Generation 4 Aurora Series sets new benchmark in chromatography

Australia-based IonOpticks, developer of chromatography columns for mass spectrometry research, has announced the launch of its 4th Generation of Aurora Series columns.

1 mins

Sartorius expands manufacturing and R&D capacities for innovative bioprocess solutions in France

The life science group Sartorius recently celebrated the completion of a multi-year capacity expansion project at the headquarters of its French sub-group Sartorius Stedim Biotech in Aubagne.

1 mins

Qiagen inks new partnership to develop oncology assays

Qiagen has announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics.

1 mins

ThinkCyte unveils cloud-based platform for AI-driven cell morphology data analysis

ThinkCyte, a Japan-based life science company pioneering advanced artificial intelligence (AI)-powered cell analysis and sorting technologies, has announced the precommercial launch of MorphoScan Cloud, its new cloud-based platform designed for flexible data access, faster processing, and advanced AI– driven analysis.

1 mins

Waters enhances Alliance iS HPLC System software

Waters Corporation has announced the release of version 2.0 of the Alliance iS HPLC System software, a significant advancement that provides full end-to-end traceability and enhanced data security for the pharmaceutical industry.

1 mins

PacBio expands distribution in China gaining access to new clinical lab networks

PacBio, a leading provider of high-quality, highly accurate sequencing solutions, has announced the appointment of Haorui Gene, a globally recognised leader in blood typing genomics, as an official distributor in China.

1 mins

Riding High on China & India Diabetes, Obesity Surge

Semaglutide, a drug used for diabetes and weight management, is produced by Novo Nordisk and sold under the brand names Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management.

2 mins

Lea todas las historias de BioSpectrum Asia

BioSpectrum Asia Description:

Editor: MM-Activ-Sci-Tech-Communication

Categoría: Business

Idioma: English

Frecuencia: Monthly

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.

* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.

* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.

* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.

* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.